Skip to main content
Top
Published in: Diabetologia 1/2016

01-01-2016 | Article

The insulin resistance phenotype (muscle or liver) interacts with the type of diet to determine changes in disposition index after 2 years of intervention: the CORDIOPREV-DIAB randomised clinical trial

Authors: Ruth Blanco-Rojo, Juan F. Alcala-Diaz, Suzan Wopereis, Pablo Perez-Martinez, Gracia M. Quintana-Navarro, Carmen Marin, Jose M. Ordovas, Ben van Ommen, Francisco Perez-Jimenez, Javier Delgado-Lista, Jose Lopez-Miranda

Published in: Diabetologia | Issue 1/2016

Login to get access

Abstract

Aims/hypothesis

The aim of the study was to determine whether basal insulin resistance (IR) phenotype (muscle and/or liver) determines the effect of long-term consumption of a Mediterranean diet or a low-fat diet on tissue-specific IR and beta cell function.

Methods

The study was performed in 642 patients included in The effect of an olive oil rich Mediterranean diet on type 2 diabetes mellitus risk and incidence study (CORDIOPREV-DIAB). A total of 327 patients were randomised to a Mediterranean diet (35% fat; 22% from monounsaturated fatty acids) and 315 to a low-fat diet (<28% fat). At baseline, the patients were classified into four phenotypes according to the type of IR: (1) no IR; (2) muscle IR; (3) liver IR; (4) muscle + liver IR. The hepatic insulin resistance index (HIRI), muscular insulin sensitivity index (MISI) and disposition index were analysed at baseline and after 2 years of follow-up.

Results

At baseline, 322 patients presented no IR, 106 presented muscle IR, 109 presented liver IR, and 105 presented muscle + liver IR. With both dietary interventions, HIRI decreased in all patients (p < 0.001) and MISI increased in muscle IR and muscle + liver IR patients (p < 0.01). Long-term intake of the Mediterranean diet increased the disposition index and insulinogenic index in the muscle IR patients (p = 0.042 and p = 0.044, respectively) and the disposition index in the muscle + liver IR patients (p = 0.048), whereas the low-fat diet increased the disposition index in the liver IR patients (p = 0.017).

Conclusions/interpretation

Although both diets improve insulin sensitivity, there are differences based on basal IR phenotypes. Moreover, according to insulinogenic and disposition index data, a low-fat diet might be more beneficial to patients with liver IR, whereas patients with muscle IR and muscle + liver IR might benefit more from a Mediterranean diet.
Trial registration ClinicalTrials.gov NCT00924937

Funding

The study was supported by the Ministerio de Economia y Competitividad (AGL2012/39615) and by the Ministerio de Ciencia e Innovacion (PIE14/00005 and PI13/00023)
Appendix
Available only for authorised users
Literature
1.
go back to reference World Health Organization (2008) 2008-2013 action plan for the global strategy for the prevention and control of noncommunicable diseases: prevent and control cardiovascular diseases, cancers, chronic respiratory diseases and diabetes. WHO, Geneva World Health Organization (2008) 2008-2013 action plan for the global strategy for the prevention and control of noncommunicable diseases: prevent and control cardiovascular diseases, cancers, chronic respiratory diseases and diabetes. WHO, Geneva
2.
go back to reference DeFronzo RA (2010) Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53:1270–1287PubMedCentralCrossRefPubMed DeFronzo RA (2010) Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53:1270–1287PubMedCentralCrossRefPubMed
3.
go back to reference Matthaei S, Stumvoll M, Kellerer M, Haring HU (2000) Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 21:585–618PubMed Matthaei S, Stumvoll M, Kellerer M, Haring HU (2000) Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 21:585–618PubMed
4.
go back to reference Weir GC, Bonner-Weir S (2004) Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53(Suppl 3):S16–S21CrossRefPubMed Weir GC, Bonner-Weir S (2004) Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53(Suppl 3):S16–S21CrossRefPubMed
5.
go back to reference Salas-Salvado J, Martinez-Gonzalez MA, Bullo M, Ros E (2011) The role of diet in the prevention of type 2 diabetes. Nutr Metab Cardiovasc Dis 21(Suppl 2):B32–B48CrossRefPubMed Salas-Salvado J, Martinez-Gonzalez MA, Bullo M, Ros E (2011) The role of diet in the prevention of type 2 diabetes. Nutr Metab Cardiovasc Dis 21(Suppl 2):B32–B48CrossRefPubMed
6.
go back to reference Lopez-Miranda J, Perez-Jimenez F, Ros E et al (2010) Olive oil and health: summary of the II international conference on olive oil and health consensus report, Jaen and Cordoba (Spain) 2008. Nutr Metab Cardiovasc Dis 20:284–294CrossRefPubMed Lopez-Miranda J, Perez-Jimenez F, Ros E et al (2010) Olive oil and health: summary of the II international conference on olive oil and health consensus report, Jaen and Cordoba (Spain) 2008. Nutr Metab Cardiovasc Dis 20:284–294CrossRefPubMed
7.
go back to reference Salas-Salvado J, Bullo M, Babio N et al (2011) Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care 34:14–19PubMedCentralCrossRefPubMed Salas-Salvado J, Bullo M, Babio N et al (2011) Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care 34:14–19PubMedCentralCrossRefPubMed
8.
go back to reference American Diabetes Association (2014) Standards of medical care in diabetes—2014. Diabetes Care 37(Suppl 1):S14–S80CrossRef American Diabetes Association (2014) Standards of medical care in diabetes—2014. Diabetes Care 37(Suppl 1):S14–S80CrossRef
9.
10.
go back to reference Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Järvinen H (2004) Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169–2176CrossRefPubMed Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Järvinen H (2004) Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169–2176CrossRefPubMed
11.
go back to reference Garcia-Rios A, Gomez-Delgado FJ, Garaulet M et al (2014) Beneficial effect of CLOCK gene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in the patients with metabolic syndrome. Chronobiol Int 31:401–408CrossRefPubMed Garcia-Rios A, Gomez-Delgado FJ, Garaulet M et al (2014) Beneficial effect of CLOCK gene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in the patients with metabolic syndrome. Chronobiol Int 31:401–408CrossRefPubMed
12.
go back to reference Perez-Martinez P, Alcala-Diaz JF, Delgado-Lista J et al (2014) Metabolic phenotypes of obesity influence triglyceride and inflammation homoeostasis. Eur J Clin Invest 44:1053–1064CrossRefPubMed Perez-Martinez P, Alcala-Diaz JF, Delgado-Lista J et al (2014) Metabolic phenotypes of obesity influence triglyceride and inflammation homoeostasis. Eur J Clin Invest 44:1053–1064CrossRefPubMed
13.
go back to reference Portaluppi F, Smolensky MH, Touitou Y (2010) Ethics and methods for biological rhythm research on animals and human beings. Chronobiol Int 27:1911–1929CrossRefPubMed Portaluppi F, Smolensky MH, Touitou Y (2010) Ethics and methods for biological rhythm research on animals and human beings. Chronobiol Int 27:1911–1929CrossRefPubMed
14.
go back to reference Fernandez-Ballart JD, Pinol JL, Zazpe I et al (2010) Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. Br J Nutr 103:1808–1816CrossRefPubMed Fernandez-Ballart JD, Pinol JL, Zazpe I et al (2010) Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. Br J Nutr 103:1808–1816CrossRefPubMed
15.
go back to reference Estruch R, Ros E, Salas-Salvadó J et al (2013) Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368:1279–1290CrossRefPubMed Estruch R, Ros E, Salas-Salvadó J et al (2013) Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368:1279–1290CrossRefPubMed
16.
go back to reference Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed
17.
go back to reference Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA (2007) Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 30:89–94CrossRefPubMed Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA (2007) Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 30:89–94CrossRefPubMed
18.
go back to reference Song Y, Manson JE, Tinker L et al (2007) Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women’s Health Initiative Observational Study. Diabetes Care 30:1747–1752PubMedCentralCrossRefPubMed Song Y, Manson JE, Tinker L et al (2007) Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women’s Health Initiative Observational Study. Diabetes Care 30:1747–1752PubMedCentralCrossRefPubMed
19.
go back to reference Hanson RL, Pratley RE, Bogardus C et al (2000) Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 151:190–198CrossRefPubMed Hanson RL, Pratley RE, Bogardus C et al (2000) Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 151:190–198CrossRefPubMed
20.
go back to reference Tang W, Fu Q, Zhang Q et al (2014) The association between serum uric acid and residual beta -cell function in type 2 diabetes. J Diabetes Res 2014:709691PubMedCentralPubMed Tang W, Fu Q, Zhang Q et al (2014) The association between serum uric acid and residual beta -cell function in type 2 diabetes. J Diabetes Res 2014:709691PubMedCentralPubMed
21.
go back to reference Abdul-Ghani MA, Matsuda M, DeFronzo RA (2008) Strong association between insulin resistance in liver and skeletal muscle in non-diabetic subjects. Diabet Med 25:1289–1294PubMed Abdul-Ghani MA, Matsuda M, DeFronzo RA (2008) Strong association between insulin resistance in liver and skeletal muscle in non-diabetic subjects. Diabet Med 25:1289–1294PubMed
22.
go back to reference Pan XR, Li GW, Hu YH et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544CrossRefPubMed Pan XR, Li GW, Hu YH et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544CrossRefPubMed
23.
go back to reference Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefPubMed Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefPubMed
24.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed
25.
go back to reference Schwingshackl L, Missbach B, Konig J, Hoffmann G (2014) Adherence to a Mediterranean diet and risk of diabetes: a systematic review and meta-analysis. Public Health Nutr: 1-8 Schwingshackl L, Missbach B, Konig J, Hoffmann G (2014) Adherence to a Mediterranean diet and risk of diabetes: a systematic review and meta-analysis. Public Health Nutr: 1-8
26.
go back to reference Esposito K, Chiodini P, Maiorino MI, Bellastella G, Panagiotakos D, Giugliano D (2014) Which diet for prevention of type 2 diabetes? A meta-analysis of prospective studies. Endocrine 47:107–116CrossRefPubMed Esposito K, Chiodini P, Maiorino MI, Bellastella G, Panagiotakos D, Giugliano D (2014) Which diet for prevention of type 2 diabetes? A meta-analysis of prospective studies. Endocrine 47:107–116CrossRefPubMed
27.
go back to reference Salas-Salvado J, Bullo M, Estruch R et al (2014) Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. Ann Intern Med 160:1–10CrossRefPubMed Salas-Salvado J, Bullo M, Estruch R et al (2014) Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. Ann Intern Med 160:1–10CrossRefPubMed
28.
go back to reference Faerch K, Borch-Johnsen K, Holst JJ, Vaag A (2009) Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia 52:1714–1723CrossRefPubMed Faerch K, Borch-Johnsen K, Holst JJ, Vaag A (2009) Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia 52:1714–1723CrossRefPubMed
30.
go back to reference Sleiman D, Al-Badri MR, Azar ST (2015) Effect of Mediterranean diet in diabetes control and cardiovascular risk modification: a systematic review. Front Public Health 3:69PubMedCentralCrossRefPubMed Sleiman D, Al-Badri MR, Azar ST (2015) Effect of Mediterranean diet in diabetes control and cardiovascular risk modification: a systematic review. Front Public Health 3:69PubMedCentralCrossRefPubMed
31.
go back to reference Paniagua JA, de la Sacristana AG, Sanchez E et al (2007) A MUFA-rich diet improves postprandial glucose, lipid and GLP-1 responses in insulin-resistant subjects. J Am Coll Nutr 26:434–444CrossRefPubMed Paniagua JA, de la Sacristana AG, Sanchez E et al (2007) A MUFA-rich diet improves postprandial glucose, lipid and GLP-1 responses in insulin-resistant subjects. J Am Coll Nutr 26:434–444CrossRefPubMed
32.
go back to reference Faerch K, Brons C, Alibegovic AC, Vaag A (2010) The disposition index: adjustment for peripheral vs hepatic insulin sensitivity? J Physiol 588:759–764PubMedCentralCrossRefPubMed Faerch K, Brons C, Alibegovic AC, Vaag A (2010) The disposition index: adjustment for peripheral vs hepatic insulin sensitivity? J Physiol 588:759–764PubMedCentralCrossRefPubMed
33.
go back to reference Mann JI, De Leeuw I, Hermansen K et al (2004) Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 14:373–394CrossRefPubMed Mann JI, De Leeuw I, Hermansen K et al (2004) Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 14:373–394CrossRefPubMed
34.
35.
go back to reference Snel M, Jonker JT, Schoones J et al (2012) Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol 2012:983814PubMedCentralPubMed Snel M, Jonker JT, Schoones J et al (2012) Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol 2012:983814PubMedCentralPubMed
37.
go back to reference Jans A, van Hees AM, Gjelstad IM et al (2012) Impact of dietary fat quantity and quality on skeletal muscle fatty acid metabolism in subjects with the metabolic syndrome. Metabolism 61:1554–1565CrossRefPubMed Jans A, van Hees AM, Gjelstad IM et al (2012) Impact of dietary fat quantity and quality on skeletal muscle fatty acid metabolism in subjects with the metabolic syndrome. Metabolism 61:1554–1565CrossRefPubMed
38.
go back to reference Sandoval DA, D'Alessio DA (2015) Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 95:513–548CrossRefPubMed Sandoval DA, D'Alessio DA (2015) Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 95:513–548CrossRefPubMed
Metadata
Title
The insulin resistance phenotype (muscle or liver) interacts with the type of diet to determine changes in disposition index after 2 years of intervention: the CORDIOPREV-DIAB randomised clinical trial
Authors
Ruth Blanco-Rojo
Juan F. Alcala-Diaz
Suzan Wopereis
Pablo Perez-Martinez
Gracia M. Quintana-Navarro
Carmen Marin
Jose M. Ordovas
Ben van Ommen
Francisco Perez-Jimenez
Javier Delgado-Lista
Jose Lopez-Miranda
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 1/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3776-4

Other articles of this Issue 1/2016

Diabetologia 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine